AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...

Researchers have identified in a new study that sole e-cigarette use is strongly linked with the risk of chronic obstructive ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

Older men had more cardiovascular problems, like ischemic heart disease and hypertension, and had more ER and hospital stays ...

Patients with severe asthma (4.6% of asthma patients) are more likely to be female, older, and have higher BMI than those with non-severe asthma.

AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma.

AZ’s triple-combination therapy is already approved under the brand names Breztri Aerosphere and Trixeo Aerosphere to treat ...

Dust storms in El Paso are more than just a nuisance. Discover the health risks and expert advice on staying safe.

AstraZeneca (AZN) said on Friday that it received positive results from two late-stage trials for its triple-combination ...

AstraZeneca announced on Friday that its inhaled triple-combination therapy ‘Breztri Aerosphere’ met all primary endpoints in ...

AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the ...